Recombinant Zoster

Adults who received the recombinant zoster vaccine had a significantly lower risk for dementia over the next 6 years compared with live vaccine recipients, study results published in Nature Medicine revealed.

Two doses of the recombinant zoster vaccine provided strong protection over 4 years, even in patients taking corticosteroids who are at higher risk for herpes zoster, also known as shingles, according to researchers.

Compared with unvaccinated individuals, the recombinant zoster vaccine reduces the 3-year risk for mortality and myocardial infarction among individuals aged 50 to 65 years, according to a study.

Real-world data reported in Clinical Infectious Diseases demonstrated that the recombinant zoster vaccine was more than 85% effective at preventing herpes zoster.

The recombinant zoster vaccine not only effectively prevents herpes zoster, it reduces herpes-zoster-related pain and the use of pain medication, according to data presented at IDWeek.